Bluebird Halts Gene-based Therapy Trials as Patients Diagnosed with Cancer—Stock Plummets
Two patients with sickle cell disease involved with a gene-based therapy trial now have been diagnosed with cancer, and the […]
Two patients with sickle cell disease involved with a gene-based therapy trial now have been diagnosed with cancer, and the […]
A gene therapy for patients with transfusion-dependent beta thalassemia (TDT) didn’t fare well after a thorough review by the United […]
A Philadelphia gene-therapy biotech venture just raised $88 million in investment from Johnson & Johnson and other investors, domestic and […]
Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a […]
A painful inherited blood disorder affecting millions of people, especially Black people, occurs because of a deficiency of red blood […]
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and […]
Germany-based Bayer acquired AskBio’s industry leading AAV-based gene therapy platform to accelerate its ability to bring urgently needed treatments to […]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), positioning itself as a leader in precision genetic medicine for rare diseases, recently announced positive […]
Picking up on the ongoing “Family Man” saga, in New York Court, EGT claims that Zynteglo, the Bluebird Bio product […]
Kriya Therapeutics announced today that it has secured a 51,350 square foot operational manufacturing facility in Research Triangle Park (RTP), North […]